Details About the Webinar

This Lancet Webinar is now available to view on-demand. Access is free with registration.

Are you thinking about submitting your oncology research to The Lancet Group? Join us for this Lancet Webinar where we explore the different pathways to publication for oncology content, whether you choose to submit your paper to The Lancet or one of the Lancet specialty, Regional Health, or Discovery Science journals.

Our expert editorial team guide you through the process of finding the best home for your research. Discover how our collaborative approach, including personal support and our article transfer service, can simplify your journey to publication.

During this webinar, you will:

  • Learn about the different Lancet publication options available for oncology content.

  • Understand how our article transfer service works to find the best fit for your work.

  • Gain valuable insights from our editorial teams on optimising your manuscript for success.

About the Speakers

1744711132-bc5729c923bf922f Vania Wisdom
Senior Executive Editor and Oncology Ambassador, The Lancet, UK

Vania Wisdom joined The Lancet in 2017 as a Senior Editor. She now leads the oncology strategy at The Lancet, as the Oncology Ambassador for the journal. Alongside this work, Vania handles peer review and commissioning across a broad range of subjects, including her specialist areas of oncology and haematology. Before joining The Lancet Group, she had a 14-year career as a scientific researcher in oncology, terminating with a lectureship position at the cancer research institute at University College London (UK). During her research career, Vania developed a strong academic and award-winning scientific research background in oncology, including teaching and management experience in the UK, Germany, and Portugal. She was awarded her PhD in Cancer Immunology in 2006 by Charité – Universitätsmedizin Berlin (Germany). Vania is now based in London.

1744711437-47db9175ccd8bee2 Ali Landman
Editor-in-Chief, The Lancet Medical Imaging & Theranostics, UK

Ali Landman became the founding Editor-in-Chief of The Lancet Medical Imaging & Theranostics in January, 2026. She began her editorial career as a Senior Editor at The Lancet Oncology in 2015, moving to Deputy Editor in March, 2019, and spent a year as Acting Editor-in-Chief of The Lancet Child & Adolescent Health (2024-2025). Ali earned her PhD in cancer biology at the Massachusetts Institute of Technology (Cambridge, MA, USA) and undertook post-doctoral research in translational oncology and in neurodegenerative disease at the University of California (San Francisco, CA, USA), University College London (London, UK), and the Medical Research Council (Harwell, UK) before joining The Lancet Group. Ali has a special interest in tumour imaging, theranostics, access to care, and health equity.

1744711754-3ea7663677b1c5d5 Taissa Vila
Editor-in-Chief, The Lancet Regional Health — Americas, Brazil

Taissa Vila is based in Rio de Janeiro, Brazil. She joined The Lancet Group in 2021 as the founding Editor-in-Chief of The Lancet Regional Health — Americas. Prior to that, she worked as a postdoctoral researcher at University of Maryland, Baltimore (USA), and at University of Texas at San Antonio (USA), investigating drug resistance in fungal infections. Taissa graduated with a BSc in Pharmaceutical Sciences from the Federal University of Rio de Janeiro (Brazil) and obtained both an MSc and PhD in Cell Biology/Biophysics from the same university. She is a member of The Lancet Group's Group for Racial Equality (GRacE) and co-chair of The Lancet Group's Gender and Diversity Taskforce, advocating for equity and diversity within and beyond the organisation. Taissa is particularly interested in health equity, political sciences, and the intersections of determinants of health.

1744711978-de9bb8ed43ba50a5 Julie Stacey
Editor-in-Chief, eBioMedicine, USA

Before joining the eBioMedicine team in 2014, Julie Stacey was a scientific editor at Cell Press for 10 years. She was most recently Deputy Editor at Immunity and has also served as an Editor at Cell and Molecular Cell. Julie's doctoral studies and postdoctoral work focused on influenza and hepatitis C viruses, and she received her PhD in Microbiology in 2000.

1744712259-5d163c5115e9c91b Cathi O'Hara
Publishing Director, The Lancet Group, UK

Cathi O'Hara is a member of The Lancet Leadership Team, serving as a Publishing Director for The Lancet Group. With over 25 years of experience in scientific, technical, and medical publishing, Cathi has held a variety of roles at Elsevier, including Conference Director and Executive Publisher within the Health & Medical Sciences division. Most recently, she spent seven years managing a portfolio of proprietary and society-owned oncology journals. Cathi currently oversees ten Lancet specialty journals, working closely with Editors-in-Chief and their teams to drive strategy and advance the impact and reach of The Lancet Group's publications.

Contact Info

Lancet Webinars
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country*
Profession*
Job title*
Career stage*
Lancet Webinar Event Permission
The Lancet Group will use the information you provide on this form to be in touch with you and to provide updates relating to this Lancet Webinar event. We will not share or sell your personal information. For more information, please read our privacy policy.
Privacy Policy
✓ Yes, I consent to receiving emails about this Lancet Webinar*
Marketing Permission
The Lancet Group will use the information you provide on this form to be in touch with you and to provide updates and marketing. We will not share or sell your personal information. You can unsubscribe anytime by clicking the unsubscribe link in the footer of our emails. For more information, please read our privacy policy.
Privacy Policy
✓ Yes, I consent to receiving marketing emails from The Lancet Group
By registering, you consent to receiving communications from The Lancet Group relating to this Lancet Webinar. You can unsubscribe from these emails at any time using the unsubscribe link at the bottom of the emails.